Skip to main content
SpringerLink
Log in

CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 03 September 2014

Abstract

To detect the expression of cancerous inhibitor of phosphatase 2A (CIP2A) in chronic myelocytic leukemia (CML) and investigate the mechanism underlying CIP2A knockdown-mediated cell proliferation and apoptosis as well as the interaction of CIP2A with breakpoint cluster region-Abelson leukemia virus (BCR-ABL). CIP2A mRNA and protein expression in chronic myelocytic leukemia-chronic (CML-CP) patients and healthy controls were determined by RT-PCR and Western blot. In vivo, c-Myc expression, PP2A activity, cell proliferation, and apoptosis of CML cells were detected with CIP2A depletion. In addition, the relationship among CIP2A, BCR-ABL, and tyrosine phosphatase SHP-1 was explored by depleting/overexpressing CIP2A or inhibiting BCR-ABL. The level of CIP2A mRNA was higher in CML-CP patients than healthy controls (56/74, 75.7 % vs. 1/35, 2.9 %, P < 0.001), and CIP2A protein was overexpressed in corresponding specimens. CIP2A knockdown by siRNA reduced the level of c-Myc protein and clonogenic formation, inhibited the activity of PP2A, K562 cell proliferation, and promoted cell apoptosis. Suppressing BCR-ABL by imatinib mesylate (IM) significantly decreased CIP2A expression. CIP2A knockdown decreased BCR-ABL but increased SHP-1 expression, and CIP2A overexpression had the reverse effect. CIP2A is overexpressed in CML-CP patients, and its expression may promote CML pathogenesis. CIP2A and BCR-ABL can regulate each other in a positive feedback loop. CIP2A may be a useful therapeutic target in CML-CP, particularly in patients with IM resistance. However, further studies are needed to validate the interaction between CIP2A and BCR-ABL using other tyrosine kinase inhibitors than IM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

CIP2A:

Cancerous inhibitor of PP2A

PP2A:

Protein phosphatase 2A

S62:

Serine 62

CML:

Chronic myelocytic leukemia

CP:

Chronic phase

IM:

Imatinib mesylate

PBS:

Phosphate-buffered saline

AML:

Acute myeloid leukemia

References

  1. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306(5940):239–42.

  2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550–4.

  3. Lucas C, Wang L, Austin G, Knight K, Watmough S, Shwe K, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10):1963–6.

    Article  CAS  PubMed  Google Scholar 

  4. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358–63.

    Article  PubMed  Google Scholar 

  5. Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene. 2005;24(42):6432–40.

    CAS  PubMed  Google Scholar 

  6. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood. 2005;105(12):4893–4.

    Article  CAS  PubMed  Google Scholar 

  7. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, et al. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell. 2007;129(5):969–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Schönthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001;170(1):1–13.

    Article  PubMed  Google Scholar 

  9. Sontag E. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 2001;13(1):7–16.

    Article  CAS  PubMed  Google Scholar 

  10. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–65.

    Article  CAS  PubMed  Google Scholar 

  11. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355–68.

    Article  CAS  PubMed  Google Scholar 

  12. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer. 2006;95(7):775–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092–100.

    Article  PubMed  Google Scholar 

  14. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14(12):3722–8.

    Article  CAS  PubMed  Google Scholar 

  15. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51–62.

    Article  CAS  PubMed  Google Scholar 

  16. Yi F, Ni W, Liu W, Bai J, Li W. Expression and biological role of CIP2A in human astrocytoma. Mol Med Rep. 2013;7(5):1376–80.

    CAS  PubMed  Google Scholar 

  17. Xu P, Huang Q, Xie F, Xu X-L, Shao F. Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis. Hepatogastroenterology. 2013;60(124):669–72.

    CAS  PubMed  Google Scholar 

  18. Laine A. The role of an oncoprotein CIP2A in breast cancer. Turku: University of Turku; 2013.

  19. Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther. 2010;10(7):700–2.

    Article  CAS  PubMed  Google Scholar 

  20. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29(1):113–8.

    Article  PubMed  Google Scholar 

  21. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Wang L, Gu F, Ma N, Zhang L, Bian J-M, Cao H-Y. CIP2A expression is associated with altered expression of epithelial–mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumor Biol. 2013:1–5.

  23. Shi F, Ding Y, Ju S, Wu X, Cao S. Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers. 2013;19(1):70–6.

  24. Böckelman C, Hagström J, Mäkinen L, Keski-Säntti H, Häyry V, Lundin J, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer. 2011;104(12):1890–5.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang Z-P, Cui Q-Z, Wang E-H. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18(3):857–65.

    Article  PubMed  Google Scholar 

  26. Ma L, Wen Z-S, Liu Z, Hu Z, Ma J, Chen X-Q, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One. 2011;6(5):e20159.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Zhai M, Cong L, Han Y, Tu G. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumor Biol. 2013;35(2):1123–8.

  28. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol. 2011;122(2):430–6.

    Article  CAS  PubMed  Google Scholar 

  29. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33(3):290–8.

    Article  CAS  PubMed  Google Scholar 

  30. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117(24):6660–8.

    Article  CAS  PubMed  Google Scholar 

  31. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, et al. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. Int J Med Microbiol. 2010;59(3):259–65.

    Article  CAS  Google Scholar 

  32. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten J-P, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101(11):793–805.

    Article  CAS  PubMed  Google Scholar 

  33. Liedtke M, Pandey P, Kumar S, Kharbanda S, Kufe D. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene. 1998;17(15):1889.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81170514 and 30971151), the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (The Project sponsored by SRF for ROCS, SEM), Shandong Provincial Natural Science Foundation, China (Nos. ZR2009CM002 and ZR2012HQ003), Traditional Chinese Medicine Science and Technology Development Program of Shandong Province (No. 2011-211), Colleges Science and Technology Project of Shandong Province (No. J10LF74) and the Independent Innovation Foundation of Shandong University (IIFSDU, No. 2012TS128).

Conflict of interest

The authors have declared no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Hematology, The Second Hospital of Shandong University, Jinan, 250033, People’s Republic of China

    Juandong Wang

  2. Department of Hematology, Qilu Hospital of Shandong University, No. 107, Wenhua Xi Road, Jinan, 250012, Shandong, People’s Republic of China

    Tao Huang, Jianzhi Sun, Yuan Yu & Chunyan Chen

  3. Department of Microbiology, Key Lab for Experimental Teratology of Chinese Ministry of Education, School of Medicine, Shandong University, Jinan, 250012, People’s Republic of China

    Zhifang Liu, Wenjuan Li & Jihui Jia

Authors
  1. Juandong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianzhi Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhifang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenjuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jihui Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chunyan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunyan Chen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Huang, T., Sun, J. et al. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus. Med Oncol 31, 112 (2014). https://doi.org/10.1007/s12032-014-0112-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0112-7

Keywords

Search

Navigation